IL-4Ra signaling is necessary for Thymic Stromal Lymphopoietin (TSLP)-driven type 2 inflammation

Both the IL-4/IL-13 and TSLP pathways have been proposed to drive type 2 inflammation in preclinical models of allergic disease. However, to date, only blockade of the IL-4/IL-13 pathway has demonstrated clinical efficacy in the treatment of multiple diseases with underlying type 2 signatures, including atopic dermatitis (AD), asthma and chronic sinusitis with nasal polyposis. Here, we perform a thorough mechanistic comparison of the IL-4/IL-13 and TSLP pathways in promoting type 2 inflammation.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research